FENNEC PHARMS INC
PharmaFENNEC PHARMS INC is a pharmaceutical company focused on Oncology. Key products include PEDMARK.
FENNEC PHARMS INC's Key Drugs
FENNEC PHARMS INC's core commercial portfolio centers on PEDMARK, spanning Oncology — its most strategically important drugs approved in the last 15 years.
FENNEC PHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for FENNEC PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
FENNEC PHARMS INC's Therapeutic Areas
FENNEC PHARMS INC's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
FENNEC PHARMS INC's Top Competitors
FENNEC PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
FENNEC PHARMS INC Pipeline Snapshot
Active clinical trials for FENNEC PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PEDMARK leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2022-09-20
- Latest
- 2022-09-20
- Applications
- 1